Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$7.5MCash on Hand
6.3mo Cash Runway
Follow PTN by emailGet an email when PTN pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PTN, unsubscribe in one click. Privacy
📣 What PTN Says Is Next
fourth quarter of · “The Company’s once-weekly injectable MC4R selective peptide agonist program is on track for an IND submission in the fourth quarter of calendar 2026, and its oral MC4R selective agonist program continues to advance, with a next-generation oral candidate targeted for IND submission in the first half of calendar 2027.”
Company press release, May 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
🧪 Trial & FDA Catalysts
Feb 2025 · Phase 2 · Active Trial · Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC) Registry primary completion date, not a results date
Feb 2025 · Phase 2 · Active Trial · A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Registry primary completion date, not a results date
Apr 2024 · Phase 2 · Results Expected · A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidne Registry primary completion date, not a results date
Sep 2023 · Phase 3 · Results Expected · A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye Registry primary completion date, not a results date
Oct 2020 · Phase 2 · Results Expected · Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye Registry primary completion date, not a results date
Aug 2016 · Phase 3 · Results Expected · 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypo Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not PTN's own candidates): Bremelanotide, Tirzepatide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PTN holds $7.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.6M/quarter from operations,
an estimated runway of 6.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:65 · High
Cash runway 6 months +30
Going-concern doubt in the latest 10-K +15Risks Related to Our Financial Results and Need for Financing ● Our management has determined that there is substantial doubt about our ability to continue as a going concern, which may make it more difficult and more expensive for us to raise capital.10-K, Sep 2026
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PTN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.